Literature DB >> 2889800

Stimulation of [3H]dopamine release by nicotine in rat nucleus accumbens.

P P Rowell1, L A Carr, A C Garner.   

Abstract

The mesolimbic system of the brain has been shown to be involved in the reward properties of a number of agents. It is possible that release of monoamines by nicotine in this brain area could be related to the pleasurable aspects related to cigarette smoking. In this investigation, the effect of nicotine on the release of [3H]dopamine in the nucleus accumbens of the rat was studied. It was shown that nicotine produced a concentration-dependent increase in [3H]dopamine release at concentrations of 0.1 microM and above. The increase in release was found to be almost completely calcium dependent. The nicotine-induced release was only partially blocked by the nicotinic antagonists hexamethonium and d-tubocurarine. A number of cholinergic agonists, as well as other compounds, were tested for their capacity to mimic the effect of nicotine. At equimolar concentrations there was, at most, only 50% of the activity of nicotine. The results of this study demonstrate that nicotine stimulates the release of dopamine in the nucleus accumbens at concentrations similar to those in the blood of cigarette smokers. This suggests that the release of monoamines in specific nuclei of the mesolimbic system may be an important determinant of the desire to smoke cigarettes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2889800     DOI: 10.1111/j.1471-4159.1987.tb01013.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  32 in total

1.  Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens.

Authors:  Arthur L Brody; Mark A Mandelkern; Richard E Olmstead; David Scheibal; Emily Hahn; Sharon Shiraga; Eleanor Zamora-Paja; Judah Farahi; Sanjaya Saxena; Edythe D London; James T McCracken
Journal:  Arch Gen Psychiatry       Date:  2006-07

Review 2.  Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

Authors:  Maryka Quik; Xiomara A Perez; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

Review 3.  Desensitization of central cholinergic mechanisms and neuroadaptation to nicotine.

Authors:  E L Ochoa; L Li; M G McNamee
Journal:  Mol Neurobiol       Date:  1990 Fall-Winter       Impact factor: 5.590

4.  C957T polymorphism of the dopamine D2 receptor gene modulates the effect of nicotine on working memory performance and cortical processing efficiency.

Authors:  Leslie K Jacobsen; Kenneth R Pugh; W Einar Mencl; Joel Gelernter
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

5.  Lack of effect of chronic desipramine treatment on dopaminergic activity in the nucleus accumbens of the rat.

Authors:  L Reyneke; R Allin; V A Russell; J J Taljaard
Journal:  Neurochem Res       Date:  1989-07       Impact factor: 3.996

6.  Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron.

Authors:  J L Muir; B J Everitt; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

7.  Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats.

Authors:  P Whiteaker; H S Garcha; S Wonnacott; I P Stolerman
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 8.  In vivo brain imaging of human exposure to nicotine and tobacco.

Authors:  Anil Sharma; Arthur L Brody
Journal:  Handb Exp Pharmacol       Date:  2009

9.  Nicotinic systems and cognitive function.

Authors:  E D Levin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Neuroendocrinological and neuropsychological correlates of dopaminergic function in nicotine dependence.

Authors:  Michael N Smolka; Henning Budde; Anne C Karow; Lutz G Schmidt
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.